<code id='592B89C6DA'></code><style id='592B89C6DA'></style>
    • <acronym id='592B89C6DA'></acronym>
      <center id='592B89C6DA'><center id='592B89C6DA'><tfoot id='592B89C6DA'></tfoot></center><abbr id='592B89C6DA'><dir id='592B89C6DA'><tfoot id='592B89C6DA'></tfoot><noframes id='592B89C6DA'>

    • <optgroup id='592B89C6DA'><strike id='592B89C6DA'><sup id='592B89C6DA'></sup></strike><code id='592B89C6DA'></code></optgroup>
        1. <b id='592B89C6DA'><label id='592B89C6DA'><select id='592B89C6DA'><dt id='592B89C6DA'><span id='592B89C6DA'></span></dt></select></label></b><u id='592B89C6DA'></u>
          <i id='592B89C6DA'><strike id='592B89C6DA'><tt id='592B89C6DA'><pre id='592B89C6DA'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:158
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          STAT Readout: Friday, Oct. 20 biotech updates
          STAT Readout: Friday, Oct. 20 biotech updates

          SuzanneKreiter/GlobestaffWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourb

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          Roche acquires Telavant from Roivant, adding experimental IBD treatment

          SebastienBozon/AFPviaGettyImagesRochesaidMondayitwasbuyingTelavantHoldingsfor$7.1billionupfront,pick